EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN
Purpose of the study: to assess the efficacy and safety of morphine hydrochloride in the form of 10 mg filmcoated tablets and 1 % solution for injection in cancer patients with chronic pain syndrome of strong intensity.Material and Methods. The study included 110 cancer patients with chronic pain sy...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2019-09-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1138 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699940678238208 |
|---|---|
| author | R. A. Zukov O. P. Bobrova G. N. Gildeeva D. V. Butuzova E. A. Ershova |
| author_facet | R. A. Zukov O. P. Bobrova G. N. Gildeeva D. V. Butuzova E. A. Ershova |
| author_sort | R. A. Zukov |
| collection | DOAJ |
| description | Purpose of the study: to assess the efficacy and safety of morphine hydrochloride in the form of 10 mg filmcoated tablets and 1 % solution for injection in cancer patients with chronic pain syndrome of strong intensity.Material and Methods. The study included 110 cancer patients with chronic pain syndrome of strong intensity. The study was conducted in compliance with the principles of the Helsinki Declaration, ICH GCP, GOST R 52379-2005, as well as other Russian laws regulating the conduct of clinical trials and work with opioid analgesics. Patients were randomized at a 1:1 ratio. Group I received 10 mg film-coated morphine tablets, 1 tablet orally every 4 hours for 7 days. Group II received 1 % morphine solution for injection, intramuscularly, 4 mg every 4 hours for 7 days. A Numeric Rating Scale for Pain (NRS, 0–100 mm) was used to assess the level of pain. The safety assessment was based on the collection of data on the registration of adverse events, including opioid-associated adverse effects.Results. Enteral and parenteral morphine administration for 7 days demonstrated a statistically significant decrease in the intensity of pain syndrome in cancer patients. The use of morphine hydrochloride in tablets reduced the number of additional analgesics prescribed for cancer patients. Regarding opioid-associated adverse effects, a statistically significant difference in the incidence of constipation between two groups was observed.Conclusion. The study showed that tablets and injectable dosage forms of morphine hydrochloride were comparable in efficacy and safety profile, thus predetermining the widespread clinical use of drugs produced by the domestic manufacturer in accordance with the “pain relief ladder”, proposed by WHO. |
| format | Article |
| id | doaj-art-bdb8f4f078394d8a9679f47da15c472c |
| institution | DOAJ |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2019-09-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-bdb8f4f078394d8a9679f47da15c472c2025-08-20T03:18:26ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682019-09-01184273310.21294/1814-4861-2019-18-4-27-33654EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAINR. A. Zukov0O. P. Bobrova1G. N. Gildeeva2D. V. Butuzova3E. A. Ershova4Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Clinical Oncology Center named after A.I. KryzhanovskiyProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Clinical Oncology Center named after A.I. KryzhanovskiyI.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian FederationMedical Development Agency Ltd.Russian Pharmaceutical Company «Moscow Endocrine Plant»Purpose of the study: to assess the efficacy and safety of morphine hydrochloride in the form of 10 mg filmcoated tablets and 1 % solution for injection in cancer patients with chronic pain syndrome of strong intensity.Material and Methods. The study included 110 cancer patients with chronic pain syndrome of strong intensity. The study was conducted in compliance with the principles of the Helsinki Declaration, ICH GCP, GOST R 52379-2005, as well as other Russian laws regulating the conduct of clinical trials and work with opioid analgesics. Patients were randomized at a 1:1 ratio. Group I received 10 mg film-coated morphine tablets, 1 tablet orally every 4 hours for 7 days. Group II received 1 % morphine solution for injection, intramuscularly, 4 mg every 4 hours for 7 days. A Numeric Rating Scale for Pain (NRS, 0–100 mm) was used to assess the level of pain. The safety assessment was based on the collection of data on the registration of adverse events, including opioid-associated adverse effects.Results. Enteral and parenteral morphine administration for 7 days demonstrated a statistically significant decrease in the intensity of pain syndrome in cancer patients. The use of morphine hydrochloride in tablets reduced the number of additional analgesics prescribed for cancer patients. Regarding opioid-associated adverse effects, a statistically significant difference in the incidence of constipation between two groups was observed.Conclusion. The study showed that tablets and injectable dosage forms of morphine hydrochloride were comparable in efficacy and safety profile, thus predetermining the widespread clinical use of drugs produced by the domestic manufacturer in accordance with the “pain relief ladder”, proposed by WHO.https://www.siboncoj.ru/jour/article/view/1138chronic pain syndromeoncologymorphine hydrochlorideefficacysafety |
| spellingShingle | R. A. Zukov O. P. Bobrova G. N. Gildeeva D. V. Butuzova E. A. Ershova EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN Сибирский онкологический журнал chronic pain syndrome oncology morphine hydrochloride efficacy safety |
| title | EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN |
| title_full | EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN |
| title_fullStr | EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN |
| title_full_unstemmed | EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN |
| title_short | EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN |
| title_sort | efficacy and safety of morphine hydrochloride in cancer patients with chronic pain |
| topic | chronic pain syndrome oncology morphine hydrochloride efficacy safety |
| url | https://www.siboncoj.ru/jour/article/view/1138 |
| work_keys_str_mv | AT razukov efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain AT opbobrova efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain AT gngildeeva efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain AT dvbutuzova efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain AT eaershova efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain |